2001
Impact of Clozapine Prescription on Inpatient Resource Utilization
SERNYAK M, ROSENHECK R, DESAI R, STOLAR M, RIPPER G. Impact of Clozapine Prescription on Inpatient Resource Utilization. The Journal Of Nervous And Mental Disease 2001, 189: 766-773. PMID: 11758660, DOI: 10.1097/00005053-200111000-00006.Peer-Reviewed Original ResearchConceptsInpatient resource utilizationClozapine treatmentInpatient daysComparison groupService utilization variablesMore inpatient daysClozapine prescriptionIndex dischargeRefractory schizophreniaConventional neurolepticsTypical neurolepticsClinical variablesVA databasesInpatient hospitalizationInpatient careYear treatmentUtilization variablesClozapineTreatmentNeurolepticsPatientsSchizophreniaThe Effect of Institutional Fiscal Stress on the Use of Atypical Antipsychotic Medications in the Treatment of Schizophrenia
LESLIE D, ROSENHECK R. The Effect of Institutional Fiscal Stress on the Use of Atypical Antipsychotic Medications in the Treatment of Schizophrenia. The Journal Of Nervous And Mental Disease 2001, 189: 377-383. PMID: 11434638, DOI: 10.1097/00005053-200106000-00005.Peer-Reviewed Original ResearchMeSH KeywordsAlzheimer DiseaseAntipsychotic AgentsBenzodiazepinesBudgetsClozapineComorbidityDepressive DisorderDrug CostsFemaleHealth Care CostsHealth FacilitiesHumansMaleMiddle AgedOlanzapinePirenzepinePractice Patterns, Physicians'Regression AnalysisRisperidoneSchizophreniaTreatment OutcomeUnited StatesUnited States Department of Veterans AffairsConceptsAtypical antipsychotic medicationsTreatment of schizophreniaAtypical antipsychoticsAntipsychotic medicationExpensive atypical antipsychotic medicationsVeterans AffairsPrescription drug recordsGeneralized estimation equationsDrug recordsPatientsReduced likelihoodAntipsychoticsMedicationsFacility characteristicsSchizophreniaAtypicalsFinal sampleTreatmentOlanzapineRisperidoneDetecting Improvement in Quality of Life and Symptomatology in Schizophrenia
Cramer J, Rosenheck R, Xu W, Henderson W, Thomas J, Charney D, Schizophrenia D. Detecting Improvement in Quality of Life and Symptomatology in Schizophrenia. Schizophrenia Bulletin 2001, 27: 227-234. PMID: 11354590, DOI: 10.1093/oxfordjournals.schbul.a006869.Peer-Reviewed Original Research
1999
Interrater Reliability Levels of Multiple Clinical Examiners in the Evaluation of a Schizophrenic Patient: Quality of Life, Level of Functioning, and Neuropsychological Symptomatology
Cicchetti D, Rosenheck R, Showalter D, Charney D, Cramer J. Interrater Reliability Levels of Multiple Clinical Examiners in the Evaluation of a Schizophrenic Patient: Quality of Life, Level of Functioning, and Neuropsychological Symptomatology. The Clinical Neuropsychologist 1999, 13: 157-170. PMID: 10949157, DOI: 10.1076/clin.13.2.157.1965.Peer-Reviewed Original ResearchImpact of Clozapine on Negative Symptoms and on the Deficit Syndrome in Refractory Schizophrenia
Rosenheck R, Dunn L, Peszke M, Cramer J, Xu W, Thomas J, Charney D, Schizophrenia T. Impact of Clozapine on Negative Symptoms and on the Deficit Syndrome in Refractory Schizophrenia. American Journal Of Psychiatry 1999, 156: 88-93. PMID: 9892302, DOI: 10.1176/ajp.156.1.88.Peer-Reviewed Original ResearchConceptsRefractory schizophreniaDeficit syndromeNegative symptomsPositive symptomsClozapine's effectVeterans Administration TrialEffects of clozapineImpact of clozapineNegative clinical symptomsProminent negative symptomsClozapine treatmentHospitalized patientsConventional medicationsClinical symptomsControl subjectsAdministration trialClinical subtypesAnalysis of covariancePatientsClozapineSyndromeSymptomsNegative syndromeSchizophreniaTime pointsClozapine and Suicide
Sernyak M, Hoff R, Rosenheck R. Clozapine and Suicide. Psychiatric Services 1999, 50: 116-116. PMID: 9890596, DOI: 10.1176/ps.50.1.116.Peer-Reviewed Original Research
1998
Multiple outcome assessment in a study of the cost-effectiveness of clozapine in the treatment of refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.
Rosenheck R, Cramer J, Xu W, Grabowski J, Douyon R, Thomas J, Henderson W, Charney D. Multiple outcome assessment in a study of the cost-effectiveness of clozapine in the treatment of refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. Health Services Research 1998, 33: 1237-61. PMID: 9865219, PMCID: PMC1070315.Peer-Reviewed Original ResearchConceptsCost-effectiveness ratioRefractory schizophreniaVeterans Affairs Cooperative Study GroupHigh hospital usersIncremental cost-effectiveness ratioDouble-blind trialCooperative Study GroupDisease-specific measuresVA Medical CenterStandard assessment instrumentsMeasures of symptomsMultiple outcome domainsQuality Adjusted Life YearsComposite health indexAdjusted Life YearsHealth indexStudy entryPercent confidence intervalsAverage annual costStandard treatmentCost dataRole functioningStudy groupMedical CenterSide effectsPredictors of differential response to clozapine and haloperidol
Rosenheck R, Lawson W, Crayton J, Cramer J, Xu W, Thomas J, Stolar M, Charney D, Schizophrenia F. Predictors of differential response to clozapine and haloperidol. Biological Psychiatry 1998, 44: 475-482. PMID: 9777179, DOI: 10.1016/s0006-3223(98)00117-6.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAntipsychotic AgentsClozapineDouble-Blind MethodDrug ResistanceFemaleHaloperidolHumansMalePsychiatric Status Rating ScalesQuality of LifeRacial GroupsSchizophreniaSchizophrenic PsychologySocial SupportTreatment OutcomeUnited StatesUnited States Department of Veterans AffairsConceptsQuality of lifeThree-month outcomeOnset of schizophreniaSeverity of symptomsGreater symptom reductionGreater improvementRefractory patientsRefractory schizophreniaClozapine treatmentHospital daysClinical predictorsExtrapyramidal symptomsHospitalized patientsClinical trialsBaseline predictorsSample patientsSide effectsSymptom reductionClozapinePatientsSymptomsHigher symptomsHigh levelsHaloperidolMultiple regression analysis
1997
A Comparison of Clozapine and Haloperidol in Hospitalized Patients with Refractory Schizophrenia
Rosenheck R, Cramer J, Xu W, Thomas J, Henderson W, Frisman L, Fye C, Charney D. A Comparison of Clozapine and Haloperidol in Hospitalized Patients with Refractory Schizophrenia. New England Journal Of Medicine 1997, 337: 809-815. PMID: 9295240, DOI: 10.1056/nejm199709183371202.Peer-Reviewed Original ResearchConceptsClozapine groupExtrapyramidal side effectsHaloperidol groupRefractory schizophreniaSide effectsAntipsychotic drugsDouble-blind comparative studyVeterans Affairs Medical CenterMore outpatient servicesNegative Syndrome ScaleComparison of clozapineLower symptom levelsSimilar overall costsHospitalized patientsTreat analysisTardive dyskinesiaPsychiatric reasonsLower incidenceMedical CenterOutpatient servicesHospital usePatientsSyndrome ScaleClozapineHaloperidol
1995
Clozapine's cost effectiveness.
Rosenheck R, Charney D, Frisman L, Cramer J. Clozapine's cost effectiveness. American Journal Of Psychiatry 1995, 152: 152-3. PMID: 7802113.Peer-Reviewed Original Research
1993
Who Should Receive High-cost Mental Health Treatment and for How Long?
Rosenheck R, Massari L, Frisman L. Who Should Receive High-cost Mental Health Treatment and for How Long? Schizophrenia Bulletin 1993, 19: 843-852. PMID: 8303231, DOI: 10.1093/schbul/19.4.843.Peer-Reviewed Original ResearchConceptsMental health treatmentInpatient costsCost offsetsHealth treatmentLarger mental health systemVeterans Affairs Medical CenterInpatient service useAverage inpatient costCost-effectiveness studiesFrequent hospital usersCost of treatmentMental health systemHigh-cost interventionsHigh treatment costsHigh-cost treatmentsClinical effectivenessInpatient treatmentMedical CenterHospital useService useSchizophrenia patientsPatientsInpatient expensesExpensive treatmentHealth system